Advanced Medical Solutions Group PLC (AMS), the UK-based specialist medical device manufacturer, has disclosed that Société Générale crossed the 5% voting rights threshold in the company on 11 November 2026. The French banking group's holding rose to 5.122465% from a previously notified position of 3.929347%, representing 11,327,885 direct voting rights. The notification, completed in London on 12 November 2026, was made under the UK's Disclosure and Transparency Rules and filed via a TR-1 standard form.

Key Points

  • Advanced Medical Solutions Group PLC (AMS) — UK-listed specialist wound care and surgical products manufacturer
  • Société Générale crossed the 5% voting rights threshold on 11 November 2026, triggering a mandatory regulatory disclosure
  • Total voting rights held: 11,327,885 shares, equating to 5.122465%; prior notified position was 3.929347%
  • Investors may watch whether Société Générale increases its position further, which would require additional TR-1 disclosures

Société Générale's Direct Voting Rights Position in AMS Now Stands at 5.122465%

According to the TR-1 notification filed with Advanced Medical Solutions Group PLC, all 11,327,885 voting rights held by Société Générale are classified as direct voting rights under DTR5.1. The filing confirms that the French bank holds no indirect voting rights and no financial instruments carrying economic exposure to AMS shares. The previous notified position stood at 3.929347%, meaning the increase represents a meaningful step-up in Société Générale's declared stake, sufficient to breach the 5% threshold that mandates formal disclosure under UK market transparency rules.

Advanced Medical Solutions Group Operates in the UK Specialist Wound Care and Tissue-Sealing Sector

Advanced Medical Solutions Group PLC is a UK issuer incorporated with ISIN GB0004536594. The company develops and manufactures products for the advanced wound care and surgical markets, supplying healthcare providers with items such as tissue adhesives, haemostats, and wound closure devices. These products serve clinical settings across multiple geographies, positioning AMS within a sector driven by evolving surgical protocols and healthcare procurement cycles. As a UK-listed medical device business, it is subject to FCA Disclosure and Transparency Rules, which require major shareholders to report threshold crossings promptly.

Société Générale Confirms No Controlling Entity Links or Financial Instruments in This Holding

The notification states that Société Générale is not controlled by any natural person or legal entity in connection with this holding, and that it does not control any other undertaking holding an interest in AMS. No proxy voting arrangements, financial instruments, or convertible securities form any part of the declared position. The announcement was completed in London on 12 November 2026, one day after the threshold was crossed, meeting the standard regulatory timeline for such disclosures under DTR5.

What the 5% Threshold Crossing Means for AMS Shareholder Structure Transparency

Under UK transparency regulations, crossing the 5% voting rights threshold obligates the holder to file a formal TR-1 notification, bringing the position into the public domain. Investors monitoring AMS's shareholder register will note that Société Générale now ranks as a significant declared holder. Any further acquisition that pushes the position above 6% would trigger a further notification requirement. The company did not disclose any commercial or strategic context for the change in Société Générale's holding in this announcement.